Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

Aim: To develop a microsimulation model to assess the potential health economic impact of software-assisted MRI in detecting disease activity or progression in relapsing-remitting multiple sclerosis (RRMS) patients. Methods: We develop a simulated decision analytical model based on a hypothetical co...

Full description

Bibliographic Details
Main Authors:	Diana M. Sima, Giovanni Esposito, Wim Van Hecke, Annemie Ribbens, Guy Nagels, Dirk Smeets
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Brain Sciences
Subjects:	relapsing-remitting multiple sclerosis (RRMS) magnetic resonance imaging (MRI) brain MRI analysis software non-evidence of disease activity (NEDA) Markov model
Online Access:	https://www.mdpi.com/2076-3425/11/12/1570

Similar Items

Peginterferon beta-1a – nowa postać interferonu beta-1a
by: Zdzisław Maciejek, et al.
Published: (2015-11-01)

Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice
by: Carlos Guevara, et al.
Published: (2019-07-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
by: Masoud Ghiasian, et al.
Published: (2024-02-01)

Longitudinal cortex reorganization and white matter tracts structural changes analysis in relapsing-remitting multiple sclerosis patients with hand palsy
by: S. N. Kulikova, et al.
Published: (2017-02-01)

Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis
by: Nupur Greene, et al.
Published: (2023-07-01)

De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: the initial Iranian experience
by: Sepideh Paybast, et al.
Published: (2025-10-01)

Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
by: Ratthaporn Boonsuth, et al.
Published: (2021-11-01)

Multiple Sclerosis as a Moderator in the Dynamics of Interoceptive Awareness and Emotion Dysregulation
by: Elnaz Melhi, et al.
Published: (2025-03-01)

Assessing ‘no evidence of disease activity’ status in patients with relapsing–remitting multiple sclerosis: a long-term follow-up
by: Chiara Zilli, et al.
Published: (2023-08-01)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01)

Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis
by: Maria Teresa Cassiano, et al.
Published: (2020-01-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
by: Arkadiusz Bydliński, et al.
Published: (2024-05-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
by: VIVIAN M. ANDRADE, et al.
Published: (1999-09-01)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
by: Anthony Traboulsee, et al.
Published: (2018-09-01)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
by: Sherein G. Elgendy, et al.
Published: (2021-10-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
by: Ali Khatibi, et al.
Published: (2020-03-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Hippocampal volume in cases of relapsing remitting multiple sclerosis and its correlation with cognitive impairment
by: Khaled Eltoukhy, et al.
Published: (2023-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Explainable Artificial Intelligence to predict clinical outcomes in type 1 diabetes and relapsing-remitting multiple sclerosis adult patients
by: Anusha Ihalapathirana, et al.
Published: (2023-01-01)

Investigation of oxidative stress in relapse and remission periods of patients with relapsing-Remitting multiple sclerosis
by: Samet Oncel, et al.
Published: (2021-01-01)

Functional Connectivity Alterations Reveal Complex Mechanisms Based on Clinical and Radiological Status in Mild Relapsing Remitting Multiple Sclerosis
by: Gloria Castellazzi, et al.
Published: (2018-08-01)

Early derangement of axonal mitochondria occurs in a mouse model of progressive but not relapsing-remitting multiple sclerosis
by: Daniela Buonvicino, et al.
Published: (2023-03-01)

Diffusion tensor imaging of thalamus in relapsing⁃remitting multiple sclerosis patients
by: Yun⁃yun DUAN, et al.
Published: (2012-04-01)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
by: Sainz de la Maza S, et al.
Published: (2023-06-01)

Headache first manifestation of Multiple Sclerosis (PP-19)
by: Fatemeh Abrishamchi
Published: (2023-01-01)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
by: Havrdova E, et al.
Published: (2017-10-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: Boncho Grigorov, et al.
Published: (2020-12-01)

Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity
by: Luana Gilio, et al.
Published: (2022-08-01)

Automated quantification of deep grey matter structures and white matter lesions using magnetic resonance imaging in relapsing remission multiple sclerosis
by: Mina Rizkallah, et al.
Published: (2021-09-01)

Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
by: Carlo Lazzaro, et al.
Published: (2025-01-01)

[Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]
by: Lorenzo Giovanni Mantovani, et al.
Published: (2017-12-01)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
by: Konstantina Chalkou, et al.
Published: (2021-10-01)

Relapsing and Remitting Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Association With Infection and Vaccination: A Case Report
by: Simon Moubarak, et al.
Published: (2023-01-01)